- Home
- XPEL vs PRTA Comparison
XPEL vs PRTA Comparison
Compare XPEL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- PRTA
- Stock Information
- Founded
- XPEL 1999
- PRTA 2012
- Country
- XPEL United States
- PRTA Ireland
- Employees
- XPEL N/A
- PRTA N/A
- Industry
- XPEL Industrial Specialties
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- PRTA Health Care
- Exchange
- XPEL Nasdaq
- PRTA Nasdaq
- Market Cap
- XPEL 991.5M
- PRTA 809.8M
- IPO Year
- XPEL N/A
- PRTA N/A
- Fundamental
- Price
- XPEL $35.97
- PRTA $4.59
- Analyst Decision
- XPEL Strong Buy
- PRTA Buy
- Analyst Count
- XPEL 1
- PRTA 9
- Target Price
- XPEL $58.00
- PRTA $27.67
- AVG Volume (30 Days)
- XPEL 248.6K
- PRTA 2.8M
- Earning Date
- XPEL 05-06-2025
- PRTA 05-08-2025
- Dividend Yield
- XPEL N/A
- PRTA N/A
- EPS Growth
- XPEL N/A
- PRTA N/A
- EPS
- XPEL 1.71
- PRTA N/A
- Revenue
- XPEL $434,101,000.00
- PRTA $137,935,000.00
- Revenue This Year
- XPEL $11.20
- PRTA N/A
- Revenue Next Year
- XPEL $11.18
- PRTA $122.59
- P/E Ratio
- XPEL $20.97
- PRTA N/A
- Revenue Growth
- XPEL 8.38
- PRTA 54.55
- 52 Week Low
- XPEL $24.25
- PRTA $4.32
- 52 Week High
- XPEL $48.58
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- XPEL 57.00
- PRTA 19.53
- Support Level
- XPEL $35.62
- PRTA $4.32
- Resistance Level
- XPEL $36.67
- PRTA $4.94
- Average True Range (ATR)
- XPEL 1.12
- PRTA 0.52
- MACD
- XPEL -0.29
- PRTA -0.15
- Stochastic Oscillator
- XPEL 31.95
- PRTA 7.24
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).